FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110431176> ?p ?o ?g. }

• W2110431176 endingPage "D61" @default.
• W2110431176 startingPage "D50" @default.
• W2110431176 abstract "Prevention of restenosis after successful percutaneous transluminal coronary balloon angioplasty (PTCA) continues to present the greatest therapeutic challenge in interventional cardiology. Experimental and pathological studies describe restenosis as no more than the biologic healing response to arterial injury. Studies of serial quantitative coronary angiography have demonstrated that this biologic process may be measured as the loss in minimal luminal diameter (MLD) from post-PTCA to follow-up angiography and that it is essentially ubiquitous and normally distributed. Thus, quantitative coronary angiography has become the gold standard for evaluation of the angiographic outcome of clinical trials of new agents and devices aimed at prevention of restenosis. The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors inhibit biosynthesis of mevalonate, a precursor of non-sterol compounds involved in cell proliferation, and thus may control the neointimal response, which forms the kernel of restenosis. Experimental evidence suggests that fluvastatin may exert a greater direct inhibitory effect on proliferating vascular myocytes than other HMG-CoA reductase inhibitors, independent of any lipid-lowering action. The Fluvastatin Angioplasty Restenosis (FLARE) Trial was conceived, in collaboration between the Thoraxcenter, Erasmus University, Rotterdam, The Netherlands, and Sandoz Pharma, to evaluate the ability of fluvastatin 40 mg twice daily to reduce restenosis after successful single-lesion PTCA. Treatment of suitable patients begins 2 weeks before PTCA and continues after successful PTCA (residual diameter stenosis < 50%, without major cardiac complications) to follow-up angiography at 26 +/- 2 weeks. Restenosis is measured by quantitative coronary angiography at a core laboratory as the loss in MLD from post-PTCA to follow-up angiography. It is calculated (90% power, alpha = 0.05) that 730 evaluable patients will be needed to test the hypothesis that fluvastatin will reduce the expected post-PTCA loss in MLD by 40%. Serial lipid analysis will be carried out at a central laboratory. Trial evaluation is focused on the primary endpoint (change in MLD) but includes primary clinical endpoints (death, myocardial infarction, or the need for coronary artery bypass graft surgery or reintervention up to 40 weeks after PTCA) as well as secondary and tertiary clinical, angiographic, and laboratory endpoints. According to this methodologic approach, the effect of fluvastatin in luminal renarrowing and clinical events after successful PTCA as well as possible associations of lipid parameters with restenosis can be comprehensively investigated." @default.
• W2110431176 created "2016-06-24" @default.
• W2110431176 creator A5022649152 @default.
• W2110431176 creator A5046735873 @default.
• W2110431176 creator A5048047555 @default.
• W2110431176 creator A5051378258 @default.
• W2110431176 creator A5060565487 @default.
• W2110431176 creator A5060925457 @default.
• W2110431176 creator A5063792624 @default.
• W2110431176 date "1994-05-01" @default.
• W2110431176 modified "2023-09-23" @default.
• W2110431176 title "Prevention of restenosis after coronary balloon angioplasty: Rationale and design of the fluvastatin angioplasty restenosis (FLARE) trial" @default.
• W2110431176 cites W1815855529 @default.
• W2110431176 cites W1964738887 @default.
• W2110431176 cites W1965967389 @default.
• W2110431176 cites W1969311477 @default.
• W2110431176 cites W1975857275 @default.
• W2110431176 cites W1986312994 @default.
• W2110431176 cites W1991570129 @default.
• W2110431176 cites W1996702475 @default.
• W2110431176 cites W2005529837 @default.
• W2110431176 cites W2008793339 @default.
• W2110431176 cites W2016678257 @default.
• W2110431176 cites W2019346066 @default.
• W2110431176 cites W2019438168 @default.
• W2110431176 cites W2020906145 @default.
• W2110431176 cites W2021111035 @default.
• W2110431176 cites W2026383150 @default.
• W2110431176 cites W2026581670 @default.
• W2110431176 cites W2039189709 @default.
• W2110431176 cites W2046947414 @default.
• W2110431176 cites W2047426600 @default.
• W2110431176 cites W2049478963 @default.
• W2110431176 cites W2049765270 @default.
• W2110431176 cites W2051904824 @default.
• W2110431176 cites W2054076946 @default.
• W2110431176 cites W2061755142 @default.
• W2110431176 cites W2064060866 @default.
• W2110431176 cites W2071124826 @default.
• W2110431176 cites W2075131249 @default.
• W2110431176 cites W2076123748 @default.
• W2110431176 cites W2077861387 @default.
• W2110431176 cites W2081038112 @default.
• W2110431176 cites W2085916658 @default.
• W2110431176 cites W2088880246 @default.
• W2110431176 cites W2106021226 @default.
• W2110431176 cites W2107392339 @default.
• W2110431176 cites W2159642184 @default.
• W2110431176 cites W2161739677 @default.
• W2110431176 cites W2171961872 @default.
• W2110431176 doi "https://doi.org/10.1016/0002-9149(94)90633-5" @default.
• W2110431176 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8198025" @default.
• W2110431176 hasPublicationYear "1994" @default.
• W2110431176 type Work @default.
• W2110431176 sameAs 2110431176 @default.
• W2110431176 citedByCount "24" @default.
• W2110431176 countsByYear W21104311762013 @default.
• W2110431176 countsByYear W21104311762015 @default.
• W2110431176 countsByYear W21104311762021 @default.
• W2110431176 crossrefType "journal-article" @default.
• W2110431176 hasAuthorship W2110431176A5022649152 @default.
• W2110431176 hasAuthorship W2110431176A5046735873 @default.
• W2110431176 hasAuthorship W2110431176A5048047555 @default.
• W2110431176 hasAuthorship W2110431176A5051378258 @default.
• W2110431176 hasAuthorship W2110431176A5060565487 @default.
• W2110431176 hasAuthorship W2110431176A5060925457 @default.
• W2110431176 hasAuthorship W2110431176A5063792624 @default.
• W2110431176 hasConcept C126322002 @default.
• W2110431176 hasConcept C164705383 @default.
• W2110431176 hasConcept C2776329913 @default.
• W2110431176 hasConcept C2778095995 @default.
• W2110431176 hasConcept C2778283817 @default.
• W2110431176 hasConcept C2778417548 @default.
• W2110431176 hasConcept C2778583881 @default.
• W2110431176 hasConcept C2780326628 @default.
• W2110431176 hasConcept C2780643987 @default.
• W2110431176 hasConcept C71924100 @default.
• W2110431176 hasConceptScore W2110431176C126322002 @default.
• W2110431176 hasConceptScore W2110431176C164705383 @default.
• W2110431176 hasConceptScore W2110431176C2776329913 @default.
• W2110431176 hasConceptScore W2110431176C2778095995 @default.
• W2110431176 hasConceptScore W2110431176C2778283817 @default.
• W2110431176 hasConceptScore W2110431176C2778417548 @default.
• W2110431176 hasConceptScore W2110431176C2778583881 @default.
• W2110431176 hasConceptScore W2110431176C2780326628 @default.
• W2110431176 hasConceptScore W2110431176C2780643987 @default.
• W2110431176 hasConceptScore W2110431176C71924100 @default.
• W2110431176 hasIssue "14" @default.
• W2110431176 hasLocation W21104311761 @default.
• W2110431176 hasLocation W21104311762 @default.
• W2110431176 hasOpenAccess W2110431176 @default.
• W2110431176 hasPrimaryLocation W21104311761 @default.
• W2110431176 hasRelatedWork W1970541033 @default.
• W2110431176 hasRelatedWork W1973239849 @default.
• W2110431176 hasRelatedWork W1994811524 @default.
• W2110431176 hasRelatedWork W2036101787 @default.
• W2110431176 hasRelatedWork W2060170468 @default.
• W2110431176 hasRelatedWork W2083809419 @default.

• next